Spoken Alpha
Mineralys Therapeutics, Inc.
Mineralys Therapeutics develops lorundrostat, an oral medication that reduces aldosterone levels to treat high blood pressure and related conditions like chronic kidney disease and sleep apnea.
Mineralys Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $2.50B market cap.
MLYS missed consensus EPS by 1.0% in Q2 FY2026, reported Aug 10, 2026.
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MLYS.
$ curl https://api.spokenalpha.com/v1/companies/MLYSFAQ
Spoken Alpha indexes MLYS's earnings call transcripts at https://spokenalpha.com/companies/MLYS. Each call links to attributed speakers and parsed analyst Q&A. Mineralys Therapeutics, Inc.'s own investor relations page is at https://ir.mineralystx.com/.
Mineralys Therapeutics, Inc. (MLYS) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
Mineralys Therapeutics, Inc. (MLYS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $-2.85 | $-0.57 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.47 | $-0.44 | -6.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-17 | $-0.40 | $-0.94 | +57.5% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.52 | $-0.61 | +14.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.66 | $-0.74 | +10.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.79 | $-0.98 | +19.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-11 | $-0.98 | $-1.08 | +9.3% | $34.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-10 | $-1.13 | $-0.83 | -36.1% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.83 | $-0.70 | -18.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.70 | $-0.67 | -4.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.61 | $-0.82 | +25.6% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.57 | $-0.76 | +25.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.31 | $-0.72 | +56.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.51 | $-0.89 | +42.7% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $-1.74 | $-1.72 | -1.2% | $0 | — | — | EODHD |
Source: EODHD. MLYS reported actuals as published; sparse fields render as —.